Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 515042, 15 pages
http://dx.doi.org/10.1155/2015/515042
Review Article

Antioxidant Strategies in the Management of Diabetic Neuropathy

1Discipline of Biochemistry, School of Life Sciences, University of KwaZulu-Natal, Westville Campus, Private Bag X54001, University Road, Durban 4000, South Africa
2Department of Biochemistry, University of Johannesburg, P.O. Box 524, Auckland Park 2002, South Africa

Received 5 June 2014; Accepted 10 September 2014

Academic Editor: Kota V. Ramana

Copyright © 2015 Ayodeji Babatunde Oyenihi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. R. Zatalia and H. Sanusi, “The role of antioxidants in the pathophysiology, complications, and management of diabetes mellitus,” The Indonesian Journal of Internal Medicine, vol. 45, no. 2, pp. 141–147, 2013. View at Google Scholar · View at Scopus
  2. A. Can, N. Akev, N. Ozsoy et al., “Effect of Aloe vera leaf gel and pulp extracts on the liver in type-II diabetic rat models,” Biological and Pharmaceutical Bulletin, vol. 27, no. 5, pp. 694–698, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Algaidi, “The effect of antioxidants on experimentally induced diabetic peripheral neuropathy in adult male albino rats,” Journal of American Science, vol. 7, no. 12, pp. 671–677, 2011. View at Google Scholar
  4. K. S. Aljabri, S. A. Bokhari, and M. J. Khan, “Glycemic changes after vitamin D supplementation in patients with type 1 diabetes mellitus and vitamin D deficiency,” Annals of Saudi Medicine, vol. 30, no. 6, pp. 454–508, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. W.-T. Wang, P. Lee, H.-W. Yeh, I. V. Smirnova, and I.-Y. Choi, “Effects of acute and chronic hyperglycemia on the neurochemical profiles in the rat brain with streptozotocin-induced diabetes detected using in vivo 1H MR spectroscopy at 9.4 T,” Journal of Neurochemistry, vol. 121, no. 3, pp. 407–417, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. J.-W. Yoon and H.-S. Jun, “Autoimmune destruction of pancreatic β cells,” The American Journal of Therapeutics, vol. 12, no. 6, pp. 580–591, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. W. Pierre, A. J. H. Gildas, M. C. Ulrich, W.-N. Modeste, N. T. Benoît, and K. Albert, “Hypoglycemic and hypolipidemic effects of Bersama engleriana leaves in nicotinamide/streptozotocin-induced type 2 diabetic rats,” BMC Complementary & Alternative Medicine, vol. 12, article 264, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Negi, A. Kumar, R. P. Joshi, P. K. Ruby, and S. S. Sharma, “Oxidative stress and diabetic neuropathy: current status of antioxidants,” Institute of Integrative Omics and Applied Biotechnology Journal, vol. 2, no. 6, pp. 71–78, 2011. View at Google Scholar · View at Scopus
  9. N. A. Al-Faris, A. D. Al-sawadi, and M. S. Alokail, “Effect of samh seeds supplementation (Mesembryanthemum forsskalei Hochst) on liver enzymes and lipid profiles of streptozotocin (STZ)-induced diabetic Wistar rats,” Saudi Journal of Biological Sciences, vol. 17, no. 1, pp. 23–28, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. S. D. M. Bandeira, L. J. S. da Fonseca, G. D. S. Guedes, L. A. Rabelo, M. O. F. Goulart, and S. M. L. Vasconcelos, “Oxidative stress as an underlying contributor in the development of chronic complications in diabetes mellitus,” International Journal of Molecular Sciences, vol. 14, no. 2, pp. 3265–3284, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Negre-Salvayre, C. Coatrieux, C. Ingueneau, and R. Salvayre, “Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors,” British Journal of Pharmacology, vol. 153, no. 1, pp. 6–20, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. O. R. Ayepola, N. N. Chegou, N. L. Brooks, and O. O. Oguntibeju, “Kolaviron, a Garcinia biflavonoid complex ameliorates hyperglycemia-mediated hepatic injury in rats via suppression of inflammatory responses,” BMC Complementary and Alternative Medicine, vol. 13, article 363, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. D. T. Graves, R. Liu, and T. W. Oates, “Diabetes-enhanced inflammation and apoptosis—impact on periodontal pathosis,” Periodontology 2000, vol. 45, no. 1, pp. 128–137, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. B. C. Callaghan, H. T. Cheng, C. L. Stables, A. L. Smith, and E. L. Feldman, “Diabetic neuropathy: clinical manifestations and current treatments,” The Lancet Neurology, vol. 11, no. 6, pp. 521–534, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Kasznicki, M. Kosmalski, A. Sliwinska et al., “Evaluation of oxidative stress markers in pathogenesis of diabetic neuropathy,” Molecular Biology Reports, vol. 39, no. 9, pp. 8669–8678, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. A. J. M. Boulton, A. I. Vinik, J. C. Arezzo et al., “Diabetic neuropathies: a statement by the American Diabetes Association,” Diabetes Care, vol. 28, no. 4, pp. 956–962, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. A. S. Shaikh and R. S. Somani, “Animal models and biomarkers of neuropathy in diabetic rodents,” Indian Journal of Pharmacology, vol. 42, no. 3, pp. 129–134, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Ziegler, C. G. H. Sohr, and J. Nourooz-Zadeh, “Oxidative stress and antioxidant defense in relation to the severity of diabetic polyneuropathy and cardiovascular autonomic neuropathy,” Diabetes Care, vol. 27, no. 9, pp. 2178–2183, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Valko, D. Leibfritz, J. Moncol, M. T. D. Cronin, M. Mazur, and J. Telser, “Free radicals and antioxidants in normal physiological functions and human disease,” The International Journal of Biochemistry and Cell Biology, vol. 39, no. 1, pp. 44–84, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. A. O. Ayeleso, O. O. Oguntibeju, and N. Brooks, “Flavonoids and their antidiabetic potentials,” in Bioactive Phytochemicals: Perspectives for Modern Medicine, vol. 1, pp. 79–106, Daya Publishing House, New Delhi, India, 2012. View at Google Scholar
  21. I. Rahman, S. K. Biswas, and A. Kode, “Oxidant and antioxidant balance in the airways and airway diseases,” European Journal of Pharmacology, vol. 533, no. 1–3, pp. 222–239, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Inoguchi, P. Li, F. Umeda et al., “High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells,” Diabetes, vol. 49, no. 11, pp. 1939–1945, 2000. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Brownlee, “Biochemistry and molecular cell biology of diabetic complications,” Nature, vol. 414, no. 6865, pp. 813–820, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Cederberg, S. Basu, and U. J. Eriksson, “Increased rate of lipid peroxidation and protein carbonylation in experimental diabetic pregnancy,” Diabetologia, vol. 44, no. 6, pp. 766–774, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Brownlee, “A radical explanation for glucose-induced β cell dysfunction,” Journal of Clinical Investigation, vol. 112, no. 12, pp. 1788–1790, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. D. A. Lepore, T. A. Shinkel, N. Fisicaro et al., “Enhanced expression of glutathione peroxidase protects islet β cells from hypoxia-reoxygenation,” Xenotransplantation, vol. 11, no. 1, pp. 53–59, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. B.-H. Chen, D.-Y. Jiang, and L.-S. Tang, “Advanced glycation end-products induce apoptosis involving the signaling pathways of oxidative stress in bovine retinal pericytes,” Life Sciences, vol. 79, no. 11, pp. 1040–1048, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. C. J. Rhodes, “Type 2 diabetes—a matter of β-cell life and death?” Science, vol. 307, no. 5708, pp. 380–384, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Lazo-de-la-Vega-Monroy and C. Fernández-Mejía, “Oxidative stress in diabetes mellitus and the role of vitamins with antioxidant actions,” in Oxidative Stress and Chronic Degenerative Diseases-A Role for Antioxidants, pp. 209–231, InTech, Hampshire, UK, 2013. View at Google Scholar
  30. R. P. Robertson, H.-J. Zhang, K. L. Pyzdrowski, and T. F. Walseth, “Preservation of insulin mRNA levels and insulin secretion in HIT cells by avoidance of chronic exposure to high glucose concentrations,” Journal of Clinical Investigation, vol. 90, no. 2, pp. 320–325, 1992. View at Publisher · View at Google Scholar · View at Scopus
  31. A. R. Saltiel and C. R. Kahn, “Insulin signalling and the regulation of glucose and lipid metabolism,” Nature, vol. 414, no. 6865, pp. 799–806, 2001. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Bloch-Damti and N. Bashan, “Proposed mechanisms for the induction of insulin resistance by oxidative stress,” Antioxidants and Redox Signaling, vol. 7, no. 11-12, pp. 1553–1567, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. J. L. Rains and S. K. Jain, “Oxidative stress, insulin signaling, and diabetes,” Free Radical Biology and Medicine, vol. 50, no. 5, pp. 567–575, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. D. Pitocco, F. Zaccardi, E. di Stasio et al., “Oxidative stress, nitric oxide, and diabetes,” The Review of Diabetic Studies, vol. 7, no. 1, pp. 15–25, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. Higaki, T. Mikami, N. Fujii et al., “Oxidative stress stimulates skeletal muscle glucose uptake through a phosphatidylinositol 3-kinase-dependent pathway,” The American Journal of Physiology: Endocrinology and Metabolism, vol. 294, no. 5, pp. E889–E897, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Ceriello, F. Mercuri, L. Quagliaro et al., “Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress,” Diabetologia, vol. 44, no. 7, pp. 834–838, 2001. View at Publisher · View at Google Scholar · View at Scopus
  37. M. E. Atabek, H. Vatansev, and I. Erkul, “Oxidative stress in childhood obesity,” Journal of Pediatric Endocrinology and Metabolism, vol. 17, no. 8, pp. 1063–1068, 2004. View at Google Scholar · View at Scopus
  38. S. Furukawa, T. Fujita, M. Shimabukuro et al., “Increased oxidative stress in obesity and its impact on metabolic syndrome,” Journal of Clinical Investigation, vol. 114, no. 12, pp. 1752–1761, 2004. View at Publisher · View at Google Scholar · View at Scopus
  39. V. Poitout and R. P. Robertson, “Glucolipotoxicity: fuel excess and β-cell dysfunction,” Endocrine Reviews, vol. 29, no. 3, pp. 351–366, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. L. I. Rachek, N. P. Thornley, V. I. Grishko, S. P. LeDoux, and G. L. Wilson, “Protection of INS-1 cells from free fatty acid-induced apoptosis by targeting hOGG1 to mitochondria,” Diabetes, vol. 55, no. 4, pp. 1022–1028, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Ceriello and R. Testa, “Antioxidant anti-inflammatory treatment in type 2 diabetes,” Diabetes care, vol. 32, pp. S232–S236, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. J. S. Johansen, A. K. Harris, D. J. Rychly, and A. Ergul, “Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical pratice,” Cardiovascular Diabetology, vol. 4, article 5, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Kiritoshi, T. Nishikawa, K. Sonoda et al., “Reactive oxygen species from mitochondria induce cyclooxygenase-2 gene expression in human mesangial cells: potential role in diabetic nephropathy,” Diabetes, vol. 52, no. 10, pp. 2570–2577, 2003. View at Publisher · View at Google Scholar · View at Scopus
  44. P. Fernyhough, S. K. Roy Chowdhury, and R. E. Schmidt, “Mitochondrial stress and the pathogenesis of diabetic neuropathy,” Expert Review of Endocrinology and Metabolism, vol. 5, no. 1, pp. 39–49, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. C. M. Casellini and A. I. Vinik, “Recent advances in the treatment of diabetic neuropathy,” Current Opinion in Endocrinology and Diabetes, vol. 13, no. 2, pp. 147–153, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Hosseini and M. Abdollahi, “Diabetic neuropathy and oxidative stress: therapeutic perspectives,” Oxidative Medicine and Cellular Longevity, vol. 2013, Article ID 168039, 15 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. L. J. Coppey, J. S. Gellett, E. P. Davidson, J. A. Dunlap, D. D. Lund, and M. A. Yorek, “Effect of antioxidant treatment of streptozotocin-induced diabetic rats on endoneurial blood flow, motor nerve conduction velocity, and vascular reactivity of epineurial arterioles of the sciatic nerve,” Diabetes, vol. 50, no. 8, pp. 1927–1937, 2001. View at Publisher · View at Google Scholar · View at Scopus
  48. I. G. Obrosova, C. van Huysen, L. Fathallah, X. C. Cao, D. A. Greene, and M. J. Stevens, “An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense,” The FASEB Journal, vol. 16, no. 1, pp. 123–125, 2002. View at Google Scholar · View at Scopus
  49. J. W. Russell, D. Golovoy, A. M. Vincent et al., “High glucose-induced oxidative stress and mitochondrial dysfunction in nuerons,” The FASEB Journal, vol. 16, no. 13, pp. 1738–1748, 2002. View at Publisher · View at Google Scholar · View at Scopus
  50. M. A. Yorek, “The role of oxidative stress in diabetic vascular and neural disease,” Free Radical Research, vol. 37, no. 5, pp. 471–480, 2003. View at Publisher · View at Google Scholar · View at Scopus
  51. E. L. Feldman and A. Vincent, “The prevalence, impact, and multifactorial pathogenesis of diabetic peripheral neuropathy,” Advanced Studies in Medicine, vol. 4, no. 8A, pp. S642–S649, 2004. View at Google Scholar · View at Scopus
  52. V. R. Drel, N. Mashtalir, O. Ilnytska et al., “The leptin-deficient (ob/ob) mouse: a new animal model of peripheral neuropathy of type 2 diabetes and obesity,” Diabetes, vol. 55, no. 12, pp. 3335–3343, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. I. G. Obrosova, O. Ilnytska, V. V. Lyzogubov et al., “High-fat diet-induced neuropathy of pre-diabetes and obesity: effects of “healthy” diet and aldose reductase inhibition,” Diabetes, vol. 56, no. 10, pp. 2598–2608, 2007. View at Publisher · View at Google Scholar · View at Scopus
  54. E. C. M. Ho, K. S. L. Lam, S. C. Yuk et al., “Aldose reductase-deficient mice are protected from delayed motor nerve conduction velocity, increased c-Jun NH2-terminal kinase activation, depletion of reduced glutathione, increased superoxide accumulation, and DNA damage,” Diabetes, vol. 55, no. 7, pp. 1946–1953, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. S.-H. Ko and B.-Y. Cha, “Diabetic peripheral neuropathy in type 2 diabetes mellitus in Korea,” Diabetes and Metabolism Journal, vol. 36, no. 1, pp. 6–12, 2012. View at Publisher · View at Google Scholar · View at Scopus
  56. A. M. Vincent, J. W. Russell, P. Low, and E. L. Feldman, “Oxidative stress in the pathogenesis of diabetic neuropathy,” Endocrine Reviews, vol. 25, no. 4, pp. 612–628, 2004. View at Publisher · View at Google Scholar · View at Scopus
  57. V. Jakus, “The role of free radicals, oxidative stress and antioxidant systems in diabetic vascular disease.,” Bratislavske Lekarske Listy, vol. 101, no. 10, pp. 541–551, 2000. View at Google Scholar · View at Scopus
  58. J. L. Edwards, A. M. Vincent, H. T. Cheng, and E. L. Feldman, “Diabetic neuropathy: mechanisms to management,” Pharmacology and Therapeutics, vol. 120, no. 1, pp. 1–34, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. D. Mahmood, B. K. Singh, and M. Akhtar, “Diabetic neuropathy: therapies on the horizon,” Journal of Pharmacy and Pharmacology, vol. 61, no. 9, pp. 1137–1145, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. G. Francis, J. Martinez, W. Liu et al., “Intranasal insulin ameliorates experimental diabetic neuropathy,” Diabetes, vol. 58, no. 4, pp. 934–945, 2009. View at Publisher · View at Google Scholar · View at Scopus
  61. T. Miyata, Y. Wada, Z. Cai et al., “Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure,” Kidney International, vol. 51, no. 4, pp. 1170–1181, 1997. View at Publisher · View at Google Scholar · View at Scopus
  62. M. Kalousová, J. Skrha, and T. Zima, “Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus,” Physiological Research, vol. 51, no. 6, pp. 597–604, 2002. View at Google Scholar · View at Scopus
  63. M. A. Lal, H. Brismar, A.-C. Eklöf, and A. Aperia, “Role of oxidative stress in advanced glycation end product-induced mesangial cell activation,” Kidney International, vol. 61, no. 6, pp. 2006–2014, 2002. View at Publisher · View at Google Scholar · View at Scopus
  64. R. H. M. King, “The role of glycation in the pathogenesis of diabetic polyneuropathy,” Journal of Clinical Pathology—Molecular Pathology, vol. 54, no. 6, pp. 400–408, 2001. View at Google Scholar · View at Scopus
  65. C. Toth, L. L. Rong, C. Yang et al., “Receptor for advanced glycation end products (RAGEs) and experimental diabetic neuropathy,” Diabetes, vol. 57, pp. 1002–1017, 2008. View at Google Scholar
  66. S. P. Wolff and R. T. Dean, “Glucose autoxidation and protein modification: the potential role of autoxidative glycosylation in diabetes,” Biochemical Journal, vol. 245, no. 1, pp. 243–250, 1987. View at Google Scholar · View at Scopus
  67. I. V. Turko, S. Marcondes, and F. Murad, “Diabetes-associated nitration of tyrosine and inactivation of succinyl-CoA:3-oxoacid CoA-transferase,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 281, no. 6, pp. H2289–H2294, 2001. View at Google Scholar · View at Scopus
  68. J. L. Evans, I. D. Goldfine, B. A. Maddux, and G. M. Grodsky, “Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes,” Endocrine Reviews, vol. 23, no. 5, pp. 599–622, 2002. View at Publisher · View at Google Scholar · View at Scopus
  69. M. G. Buse, “Hexosamines, insulin resistance, and the complications of diabetes: current status,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 290, no. 1, pp. 1–8, 2006. View at Publisher · View at Google Scholar · View at Scopus
  70. G. M. Leinninger, A. M. Vincent, and E. L. Feldman, “The role of growth factors in diabetic peripheral neuropathy,” Journal of the Peripheral Nervous System, vol. 9, no. 1, pp. 26–53, 2004. View at Publisher · View at Google Scholar · View at Scopus
  71. V. Scivittaro, M. B. Ganz, and M. F. Weiss, “AGEs induce oxidative stress and activate protein kinase C-β(II) in neonatal mesangial cells,” American Journal of Physiology: Renal Physiology, vol. 278, no. 4, pp. F676–F683, 2000. View at Google Scholar · View at Scopus
  72. S. M. Rajbhandari and M. K. Piya, “A brief review on the pathogenesis of human diabetic neuropathy: observations and postulations,” International Journal of Diabetes and Metabolism, vol. 13, no. 3, pp. 135–140, 2005. View at Google Scholar · View at Scopus
  73. A. Ceriello, “Oxidative stress and diabetes-associated complications,” Endocrine Practice, vol. 12, no. 1, pp. 60–62, 2006. View at Publisher · View at Google Scholar · View at Scopus
  74. Z. He, C. Rask-Madsen, and G. L. King, “Managing heart disease mechanisms of cardiovascular complications in diabetes and potential new pharmacological therapies,” European Heart Journal, Supplement, vol. 5, pp. B51–B57, 2003. View at Publisher · View at Google Scholar · View at Scopus
  75. F. Li, V. R. Drel, C. Szabó, M. J. Stevens, and I. G. Obrosova, “Low-dose poly(ADP-ribose) polymerase inhibitor-containing combination therapies reverse early peripheral diabetic neuropathy,” Diabetes, vol. 54, no. 5, pp. 1514–1522, 2005. View at Publisher · View at Google Scholar · View at Scopus
  76. I. G. Obrosova, W. Xu, V. V. Lyzogubov et al., “PARP inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy,” Free Radical Biology and Medicine, vol. 44, no. 6, pp. 972–981, 2008. View at Publisher · View at Google Scholar · View at Scopus
  77. S. A. Price, S. Agthong, A. B. Middlemas, and D. R. Tomlinson, “Mitogen-activated protein kinase p38 mediates reduced nerve conduction in experimental diabetic neuropathy: interactions with aldose reductase,” Diabetes, vol. 53, no. 7, pp. 1851–1856, 2004. View at Publisher · View at Google Scholar · View at Scopus
  78. R. Stavniichuk, H. Shevalye, H. Hirooka, J. L. Nadler, and I. G. Obrosova, “Interplay of sorbitol pathway of glucose metabolism, 12/15-lipoxygenase, and mitogen-activated protein kinases in the pathogenesis of diabetic peripheral neuropathy,” Biochemical Pharmacology, vol. 83, no. 7, pp. 932–940, 2012. View at Publisher · View at Google Scholar · View at Scopus
  79. K. E. Hall, A. A. F. Anders, and J. W. Wiley, “Voltage-dependent calcium currents are enhanced in dorsal root ganglion neurones from the Bio Bred/Worchester diabetic rat,” Journal of Physiology, vol. 486, no. 2, pp. 313–322, 1995. View at Google Scholar · View at Scopus
  80. A. P. Kellogg, T. D. Wiggin, D. D. Larkin, J. M. Hayes, M. J. Stevens, and R. Pop-Busui, “Protective effects of cyclooxygenase-2 gene inactivation against peripheral nerve dysfunction and intraepidermal nerve fiber loss in experimental diabetes,” Diabetes, vol. 56, no. 12, pp. 2997–3005, 2007. View at Publisher · View at Google Scholar · View at Scopus
  81. R. Stavniichuk, V. R. Drel, H. Shevalye et al., “Role of 12/15-lipoxygenase in nitrosative stress and peripheral prediabetic and diabetic neuropathies,” Free Radical Biology and Medicine, vol. 49, no. 6, pp. 1036–1045, 2010. View at Publisher · View at Google Scholar · View at Scopus
  82. I. G. Obrosova, R. Stavniichuk, V. R. Drel et al., “Different roles of 12/15-lipoxygenase in diabetic large and small fiber peripheral and autonomic neuropathies,” The American Journal of Pathology, vol. 177, no. 3, pp. 1436–1447, 2010. View at Publisher · View at Google Scholar · View at Scopus
  83. N. E. Cameron, M. A. Cotter, V. Archibald, K. C. Dines, and E. K. Maxfield, “Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in non-diabetic and streptozotocin-diabetic rats,” Diabetologia, vol. 37, no. 5, pp. 449–459, 1994. View at Publisher · View at Google Scholar · View at Scopus
  84. N. E. Cameron and M. A. Cotter, “Effects of antioxidants on nerve and vascular dysfunction in experimental diabetes,” Diabetes Research and Clinical Practice, vol. 45, no. 2-3, pp. 137–146, 1999. View at Publisher · View at Google Scholar · View at Scopus
  85. P. S. van Dam, “Oxidative stress and diabetic neuropathy: pathophysiological mechanisms and treatment perspectives,” Diabetes/Metabolism Research and Reviews, vol. 18, no. 3, pp. 176–184, 2002. View at Publisher · View at Google Scholar · View at Scopus
  86. L. J. Coppey, J. S. Gellett, E. P. Davidson, and M. A. Yorek, “Preventing superoxide formation in epineurial arterioles of the sciatic nerve from diabetic rats restores endothelium-dependent vasodilation,” Free Radical Research, vol. 37, no. 1, pp. 33–40, 2003. View at Publisher · View at Google Scholar · View at Scopus
  87. S. G. Sayyed, A. Kumar, and S. S. Sharma, “Effects of U83836E on nerve functions, hyperalgesia and oxidative stress in experimental diabetic neuropathy,” Life Sciences, vol. 79, no. 8, pp. 777–783, 2006. View at Publisher · View at Google Scholar · View at Scopus
  88. A. Kumar, R. K. Kaundal, S. Iyer, and S. S. Sharma, “Effects of resveratrol on nerve functions, oxidative stress and DNA fragmentation in experimental diabetic neuropathy,” Life Sciences, vol. 80, no. 13, pp. 1236–1244, 2007. View at Publisher · View at Google Scholar · View at Scopus
  89. G. Negi, A. Kumar, and S. S. Sharma, “Melatonin modulates neuroinflammation and oxidative stress in experimental diabetic neuropathy: effects on NF-κB and Nrf2 cascades,” Journal of Pineal Research, vol. 50, no. 2, pp. 124–131, 2011. View at Publisher · View at Google Scholar · View at Scopus
  90. A. S. Ametov, A. Barinov, P. J. Dyck et al., “The sensory symptoms of diabetic polyneuropathy are improved with α-lipoic acid: The Sydney trial,” Diabetes Care, vol. 26, no. 3, pp. 770–776, 2003. View at Publisher · View at Google Scholar · View at Scopus
  91. D. Ziegler, A. Ametov, A. Barinov et al., “Oral treatment with α-lipoic acid improves symptomatic diabetic polyneuropathy,” Diabetes Care, vol. 29, no. 11, pp. 2365–2370, 2006. View at Publisher · View at Google Scholar · View at Scopus
  92. D. Ziegler, P. A. Low, W. J. Litchy et al., “Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial,” Diabetes Care, vol. 34, no. 9, pp. 2054–2060, 2011. View at Publisher · View at Google Scholar · View at Scopus
  93. J.-H. Hong, M.-J. Kim, M.-R. Park et al., “Effects of vitamin E on oxidative stress and membrane fluidity in brain of streptozotocin-induced diabetic rats,” Clinica Chimica Acta, vol. 340, no. 1-2, pp. 107–115, 2004. View at Publisher · View at Google Scholar · View at Scopus
  94. Y. Özkan, Ö. Yilmaz, A. I. Öztürk, and Y. Erşan, “Effects of triple antioxidant combination (vitamin E, vitamin C and α-lipoic acid) with insulin on lipid and cholesterol levels and fatty acid composition of brain tissue in experimental diabetic and non-diabetic rats,” Cell Biology International, vol. 29, no. 9, pp. 754–760, 2005. View at Publisher · View at Google Scholar · View at Scopus
  95. N. Vallianou, A. Evangelopoulos, and P. Koutalas, “Alpha-lipoic acid and diabetic neuropathy,” Review of Diabetic Studies, vol. 6, no. 4, pp. 230–236, 2009. View at Publisher · View at Google Scholar · View at Scopus
  96. L. Packer, K. Kraemer, and G. Rimbach, “Molecular aspects of lipoic acid in the prevention of diabetes complications,” Nutrition, vol. 17, no. 10, pp. 888–895, 2001. View at Publisher · View at Google Scholar · View at Scopus
  97. M. Nagamatsu, K. K. Nickander, J. D. Schmelzer et al., “Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy,” Diabetes Care, vol. 18, no. 8, pp. 1160–1167, 1995. View at Publisher · View at Google Scholar · View at Scopus
  98. G. Baydas, E. Donder, M. Kiliboz et al., “Neuroprotection by α-lipoic acid in streptozotocin-induced diabetes,” Biochemistry, vol. 69, no. 9, pp. 1001–1005, 2004. View at Publisher · View at Google Scholar · View at Scopus
  99. J. L. Evans, C. J. Heymann, I. D. Goldfine, and L. A. Gavin, “Pharmacokinetics, tolerability, and fructosamine-lowering effect of a novel, controlled-release formulation of α-lipoic acid,” Endocrine Practice, vol. 8, no. 1, pp. 29–35, 2002. View at Publisher · View at Google Scholar · View at Scopus
  100. T. Tankova, S. Cherninkova, and D. Koev, “Treatment for diabetic mononeuropathy with α-lipoic acid,” International Journal of Clinical Practice, vol. 59, no. 6, pp. 645–650, 2005. View at Publisher · View at Google Scholar · View at Scopus
  101. X. Du, D. Edelstein, and M. Brownlee, “Oral benfotiamine plus α-lipoic acid normalises complication-causing pathways in type 1 diabetes,” Diabetologia, vol. 51, no. 10, pp. 1930–1932, 2008. View at Publisher · View at Google Scholar · View at Scopus
  102. E. A. Huang and S. E. Gitelman, “The effect of oral alpha-lipoic acid on oxidative stress in adolescents with type 1 diabetes mellitus,” Pediatric Diabetes, vol. 9, no. 3, pp. 69–73, 2008. View at Publisher · View at Google Scholar · View at Scopus
  103. V. Gianturco, A. Bellomo, E. D'Ottavio et al., “Impact of therapy with alpha-lipoic acid (ALA) on the oxidative stress in the controlled NIDDM: a possible preventive way against the organ dysfunction?” Archives of Gerontology and Geriatrics, vol. 49, pp. 129–133, 2009. View at Google Scholar · View at Scopus
  104. F. Bertolotto and A. Massone, “Combination of alpha lipoic acid and superoxide dismutase leads to physiological and symptomatic improvements in diabetic neuropathy,” Drugs in R and D, vol. 12, no. 1, pp. 29–34, 2012. View at Publisher · View at Google Scholar · View at Scopus
  105. J. Shakher and M. J. Stevens, “Update on the management of diabetic polyneuropathies,” Diabetes, Metabolic Syndrome and Obesity, vol. 4, pp. 289–305, 2011. View at Google Scholar
  106. A. C. Maritim, R. A. Sanders, and J. B. Watkins III, “Diabetes, oxidative stress, and antioxidants: a review,” Journal of Biochemical and Molecular Toxicology, vol. 17, no. 1, pp. 24–38, 2003. View at Publisher · View at Google Scholar · View at Scopus
  107. S. H. Salah, H. S. Abdou, and E. A. Abdel Rahim, “Modulatory effect of vitamins A, C and E mixtures against tefluthrin pesticide genotoxicity in rats,” Pesticide Biochemistry and Physiology, vol. 98, no. 2, pp. 191–197, 2010. View at Publisher · View at Google Scholar · View at Scopus
  108. M. Kunisaki, S.-E. Bursell, A. C. Clermont et al., “Vitamin E prevents diabetes-induced abnormal retinal blood flow via the diacylglycerol-protein kinase C pathway,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 269, no. 2, part 1, pp. E239–E246, 1995. View at Google Scholar · View at Scopus
  109. M. G. Çinar, S. Ülker, G. Alper, and A. Evinç, “Effect of dietary vitamin E supplementation on vascular reactivity of thoracic aorta in streptozotocin-diabetic rats,” Pharmacology, vol. 62, no. 1, pp. 56–64, 2001. View at Publisher · View at Google Scholar · View at Scopus
  110. T. I. Chang, M. Horal, S. K. Jain, F. Wang, R. Patel, and M. R. Loeken, “Oxidant regulation of gene expression and neural tube development: insights gained from diabetic pregnancy on molecular causes of neural tube defects,” Diabetologia, vol. 46, no. 4, pp. 538–545, 2003. View at Google Scholar · View at Scopus
  111. M. Hamblin, H. M. Smith, and M. F. Hill, “Dietary supplementation with vitamin E ameliorates cardiac failure in type 1 diabetic cardiomyopathy by suppressing myocardial generation of 8-iso-prostaglandin F2α and oxidized glutathione,” Journal of Cardiac Failure, vol. 13, no. 10, pp. 884–892, 2007. View at Publisher · View at Google Scholar · View at Scopus
  112. D. M. Niedowicz and D. L. Daleke, “The role of oxidative stress in diabetic complications,” Cell Biochemistry and Biophysics, vol. 43, no. 2, pp. 289–330, 2005. View at Publisher · View at Google Scholar · View at Scopus
  113. “Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico,” The Lancet, vol. 354, no. 9177, pp. 447–455, 1999. View at Publisher · View at Google Scholar
  114. S. Yusuf, “Vitamin E supplementation and cardiovascular events in high-risk patients,” The New England Journal of Medicine, vol. 342, no. 3, pp. 154–160, 2000. View at Publisher · View at Google Scholar · View at Scopus
  115. S. Pruthi, T. G. Allison, and D. D. Hensrud, “Vitamin E supplementation in the prevention of coronary heart disease,” Mayo Clinic Proceedings, vol. 76, no. 11, pp. 1131–1136, 2001. View at Publisher · View at Google Scholar · View at Scopus
  116. I.-M. Lee, N. R. Cook, J. M. Gaziano et al., “Vitamin E in the primary prevention of cardiovascular disease and cancer: the women's health study: a randomized controlled trial,” The Journal of the American Medical Association, vol. 294, no. 1, pp. 56–65, 2005. View at Publisher · View at Google Scholar · View at Scopus
  117. U. Milman, S. Blum, C. Shapira et al., “Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 2, pp. 341–347, 2008. View at Publisher · View at Google Scholar · View at Scopus
  118. T. R. Einarson, M. Garg, V. Kaur, and M. E. H. Hemels, “Composite endpoints in trials of type-2 diabetes,” Diabetes, Obesity and Metabolism, vol. 16, no. 6, pp. 492–499, 2014. View at Publisher · View at Google Scholar · View at Scopus
  119. F. Babaei-Balderlou, S. Zare, R. Heidari, and F. Farrokhi, “Effects of melatonin and vitamin E on peripheral neuropathic pain in streptozotocin-induced diabetic rats,” Iranian Journal of Basic Medical Sciences, vol. 13, no. 2, pp. 1–8, 2010. View at Google Scholar · View at Scopus
  120. J. J. Cunningham, P. L. Mearkle, and R. G. Brown, “Vitamin C: an aldose reductase inhibitor that normalizes erythrocyte sorbitol in insulin-dependent diabetes mellitus,” Journal of the American College of Nutrition, vol. 13, no. 4, pp. 344–350, 1994. View at Publisher · View at Google Scholar · View at Scopus
  121. J. Eriksson and A. Kohvakka, “Magnesium and ascorbic acid supplementation in diabetes mellitus,” Annals of Nutrition and Metabolism, vol. 39, no. 4, pp. 217–223, 1995. View at Publisher · View at Google Scholar · View at Scopus
  122. H. D. Je, C. Y. Shin, S. Y. Park et al., “Combination of vitamin C and rutin on neuropathy and lung damage of diabetes mellitus rats,” Archives of Pharmacal Research, vol. 25, no. 2, pp. 184–190, 2002. View at Publisher · View at Google Scholar · View at Scopus
  123. G. T. Fadupin, A. U. Akpoghor, and K. A. Okunade, “A comparative study of serum ascorbic acid level in people with and without type 2 diabetes in Ibadan, Nigeria,” African Journal of Medicine and Medical Sciences, vol. 36, no. 4, pp. 335–339, 2007. View at Google Scholar · View at Scopus
  124. Z. Mazloom, N. Hejazi, M.-H. Dabbaghmanesh, H.-R. Tabatabaei, A. Ahmadi, and H. Ansar, “Effect of vitamin C supplementation on postprandial oxidative stress and lipid profile in type 2 diabetic patients,” Pakistan Journal of Biological Sciences, vol. 14, no. 19, pp. 900–904, 2011. View at Publisher · View at Google Scholar · View at Scopus
  125. A. Lukačínová, J. Mojžiš, R. Beňačka, O. Rácz, and F. Ništiar, “Structure-activity relationships of preventive effects of flavonoids in alloxan-induced diabetes mellitus in rats,” Journal of Animal and Feed Sciences, vol. 17, no. 3, pp. 411–421, 2008. View at Google Scholar · View at Scopus
  126. R. J. Nijveldt, E. van Nood, D. E. C. van Hoorn, P. G. Boelens, K. van Norren, and P. A. M. van Leeuwen, “Flavonoids: a review of probable mechanisms of action and potential applications,” The American Journal of Clinical Nutrition, vol. 74, no. 4, pp. 418–425, 2001. View at Google Scholar · View at Scopus
  127. I. C. W. Arts and P. C. H. Hollman, “Polyphenols and disease risk in epidemiologic studies,” The American Journal of Clinical Nutrition, vol. 81, no. 1, pp. 317S–325S, 2005. View at Google Scholar · View at Scopus
  128. J. A. Nettleton, L. J. Harnack, C. G. Scrafford, P. J. Mink, L. M. Barraj, and D. R. Jacobs Jr., “Dietary flavonoids and flavonoid-rich foods are not associated with risk of type 2 diabetes in postmenopausal women,” Journal of Nutrition, vol. 136, no. 12, pp. 3039–3045, 2006. View at Google Scholar · View at Scopus
  129. X.-P. Cui, B.-Y. Li, H.-Q. Gao, N. Wei, W.-L. Wang, and M. Lu, “Effects of grape seed proanthocyanidin extracts on peripheral nerves in streptozocin-induced diabetic rats,” Journal of Nutritional Science and Vitaminology, vol. 54, no. 4, pp. 321–328, 2008. View at Publisher · View at Google Scholar · View at Scopus
  130. G. G. Wang, X. H. Lu, W. Li, X. Zhao, and C. Zhang, “Protective effects of luteolin on diabetic nephropathy in STZ-induced diabetic rats,” Evidence-Based Complementary and Alternative Medicine, vol. 2011, Article ID 323171, 7 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  131. S. S. Ibrahim, “Protective effect of hesperidin, a citrus bioflavonoid, on diabetes-induced brain damage in rats,” Journal of Applied Sciences Research, vol. 4, no. 1, pp. 84–95, 2008. View at Google Scholar
  132. P. Maher, R. Dargusch, J. L. Ehren, S. Okada, K. Sharma, and D. Schubert, “Fisetin lowers methylglyoxal dependent protein glycation and limits the complications of diabetes,” PLoS ONE, vol. 6, no. 6, Article ID e21226, 2011. View at Publisher · View at Google Scholar · View at Scopus
  133. T. Baluchnejadmojarad and M. Roghani, “Chronic oral epigallocatechin-gallate alleviates streptozotocin-induced diabetic neuropathic hyperalgesia in rat: Involvement of oxidative stress,” Iranian Journal of Pharmaceutical Research, vol. 11, no. 4, pp. 1243–1253, 2012. View at Google Scholar · View at Scopus
  134. M. M. Al-Enazi, “Ameliorative potential of rutin on streptozotocin-induced neuropathic pain in rat,” African Journal of Pharmacy and Pharmacology, vol. 7, no. 41, pp. 2743–2754, 2003. View at Google Scholar
  135. P. E. B. Ferreira, C. R. P. Lopes, A. M. P. Alves et al., “Diabetic neuropathy: an evaluation of the use of quercetin in the cecum of rats,” World Journal of Gastroenterology, vol. 19, no. 38, pp. 6416–6426, 2013. View at Publisher · View at Google Scholar · View at Scopus
  136. M. Naziroǧlu, M. Şimşek, H. Şimşek, N. Aydilek, Z. Özcan, and R. Atilgan, “The effects of hormone replacement therapy combined with vitamins C and E on antioxidants levels and lipid profiles in postmenopausal women with Type 2 diabetes,” Clinica Chimica Acta, vol. 344, no. 1-2, pp. 63–71, 2004. View at Publisher · View at Google Scholar · View at Scopus
  137. L. P. Roldi, R. V. F. Pereira, E. A. Tronchini et al., “Vitamin E (α-tocopherol) supplementation in diabetic rats: effects on the proximal colon,” BMC Gastroenterology, vol. 9, no. 1, article 88, 2009. View at Publisher · View at Google Scholar · View at Scopus
  138. Y.-H. Kao, R. A. Hiipakka, and S. Liao, “Modulation of endocrine systems and food intake by green tea epigallocatechin gallate,” Endocrinology, vol. 141, no. 3, pp. 980–987, 2000. View at Publisher · View at Google Scholar · View at Scopus
  139. N. Kamalakkannan and P. S. M. Prince, “Rutin improves the antioxidant status in streptozotocin-induced diabetic rat tissues,” Molecular and Cellular Biochemistry, vol. 293, no. 1-2, pp. 211–219, 2006. View at Publisher · View at Google Scholar · View at Scopus
  140. A. Kawano, H. Nakamura, S.-I. Hata, M. Minakawa, Y. Miura, and K. Yagasaki, “Hypoglycemic effect of aspalathin, a rooibos tea component from Aspalathus linearis, in type 2 diabetic model db/db mice,” Phytomedicine, vol. 16, no. 5, pp. 437–443, 2009. View at Publisher · View at Google Scholar · View at Scopus
  141. A. A. H. Fernandes, E. L. B. Novelli, A. F. Junior, and C. M. Galhardi, “Effect of naringerin on biochemical parameters in the streptozotocin-induced diabetic rats,” Brazilian Archives of Biology and Technology, vol. 52, no. 1, pp. 51–59, 2009. View at Publisher · View at Google Scholar · View at Scopus
  142. M. Torres-Piedra, R. Ortiz-Andrade, R. Villalobos-Molina et al., “A comparative study of flavonoid analogues on streptozotocin-nicotinamide induced diabetic rats: quercetin as a potential antidiabetic agent acting via 11β-Hydroxysteroid dehydrogenase type 1 inhibition,” European Journal of Medicinal Chemistry, vol. 45, no. 6, pp. 2606–2612, 2010. View at Publisher · View at Google Scholar · View at Scopus
  143. L. Pari and S. Srinivasan, “Antihyperglycemic effect of diosmin on hepatic key enzymes of carbohydrate metabolism in streptozotocin-nicotinamide-induced diabetic rats,” Biomedicine and Pharmacotherapy, vol. 64, no. 7, pp. 477–481, 2010. View at Publisher · View at Google Scholar · View at Scopus
  144. P. Nadig, R. Revankar, S. Dethe, S. Narayanswamy, and M. Aliyar, “Effect of Tinospora cordifolia on experimental diabetic neuropathy,” Indian Journal of Pharmacology, vol. 44, no. 5, pp. 580–583, 2012. View at Publisher · View at Google Scholar · View at Scopus
  145. Z. A. Malik, M. Singh, and P. L. Sharma, “Neuroprotective effect of Momordica charantia in global cerebral ischemia and reperfusion induced neuronal damage in diabetic mice,” Journal of Ethnopharmacology, vol. 133, no. 2, pp. 729–734, 2011. View at Publisher · View at Google Scholar · View at Scopus
  146. M. S. Islam and H. Choi, “Comparative effects of dietary ginger (Zingiber officinale) and garlic (Allium sativum) investigated in a type 2 diabetes model of rats,” Journal of Medicinal Food, vol. 11, no. 1, pp. 152–159, 2008. View at Publisher · View at Google Scholar · View at Scopus
  147. A. J. Afolayan and T. O. Sunmonu, “Artemisia afra jacq. ameliorates oxidative stress in the pancreas of streptozotocin-induced diabetic wistar rats,” Bioscience, Biotechnology and Biochemistry, vol. 75, no. 11, pp. 2083–2086, 2011. View at Publisher · View at Google Scholar · View at Scopus
  148. A. J. Afolayan and T. O. Sunmonu, “Protective role of Artemisia afra aqueous extract on tissue antioxidant defense systems in streptozotocin-induced diabetic rats,” African Journal of Traditional, Complementary and Alternative Medicines, vol. 10, no. 1, pp. 15–20, 2012. View at Google Scholar · View at Scopus
  149. A. B. Oyenihi, N. L. Brooks, O. O. Oguntibeju, and Y. Aboua, “Antioxidant-rich natural products and diabetes mellitus,” in Antioxidant-Rich Natural Products and Human Health, vol. 14, pp. 317–345, Intech, 2014. View at Google Scholar
  150. D. K. Patel, R. Kumar, D. Laloo, and S. Hemalatha, “Natural medicines from plant source used for therapy of diabetes mellitus: an overview of its pharmacological aspects,” Asian Pacific Journal of Tropical Disease, vol. 2, no. 3, pp. 239–250, 2012. View at Publisher · View at Google Scholar · View at Scopus
  151. N. Hotta, N. Sakamoto, Y. Shigeta, R. Kikkawa, and Y. Goto, “Clinical investigation of epalrestat, aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study,” Journal of Diabetes and its Complications, vol. 10, no. 3, pp. 168–172, 1996. View at Publisher · View at Google Scholar · View at Scopus
  152. S. Yagihashi, S. I. Yamagishi, R. I. Wada et al., “Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor,” Brain, vol. 124, no. 12, pp. 2448–2458, 2001. View at Publisher · View at Google Scholar · View at Scopus
  153. N. Hotta, T. Toyota, K. Matsuoka et al., “SNK-860 diabetic neuropathy study group: clinical efficacy of fidarestat , a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study,” Diabetes Care, vol. 24, no. 10, pp. 1776–1782, 2001. View at Publisher · View at Google Scholar
  154. N. Hotta, Y. Akanuma, R. Kawamori et al., “Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: The 3-year, multicenter, comparative aldose reductase inhibitor-diabetes complications trial,” Diabetes Care, vol. 29, no. 7, pp. 1538–1544, 2006. View at Publisher · View at Google Scholar · View at Scopus
  155. M. A. Ramirez and N. L. Borja, “Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy,” Pharmacotherapy, vol. 28, no. 5, pp. 646–655, 2008. View at Publisher · View at Google Scholar · View at Scopus
  156. V. Bril and R. A. Buchanan, “Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy,” Diabetes Care, vol. 27, no. 10, pp. 2369–2375, 2004. View at Publisher · View at Google Scholar · View at Scopus
  157. V. Bril, T. Hirose, S. Tomioka, and R. Buchanan, “Ranirestat for the management of diabetic sensorimotor polyneuropathy,” Diabetes Care, vol. 32, no. 7, pp. 1256–1260, 2009. View at Publisher · View at Google Scholar · View at Scopus
  158. K. E. Schemmel, R. S. Padiyara, and J. J. D'Souza, “Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review,” Journal of Diabetes and its Complications, vol. 24, no. 5, pp. 354–360, 2010. View at Publisher · View at Google Scholar · View at Scopus
  159. T. Kawai, I. Takei, M. Tokui et al., “Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of Nε-carboxymethyl lysine,” Journal of Diabetes and Its Complications, vol. 24, no. 6, pp. 424–432, 2010. View at Publisher · View at Google Scholar · View at Scopus
  160. S. Sharma and N. Sharma, “Epalrestat, an aldose reductase inhibitor, in diabetic neuropathy: an Indian perspective,” Annals of Indian Academy of Neurology, vol. 11, no. 4, pp. 231–235, 2008. View at Publisher · View at Google Scholar · View at Scopus
  161. M. Chattopadhyay, M. Mata, and D. J. Fink, “Continuous δ-opioid receptor activation reduces neuronal voltage-gated sodium channel (NaV1.7) levels through activation of protein kinase C in painful diabetic neuropathy,” Journal of Neuroscience, vol. 28, no. 26, pp. 6652–6658, 2008. View at Publisher · View at Google Scholar · View at Scopus
  162. M. Norcini, E. Vivoli, N. Galeotti, E. Bianchi, A. Bartolini, and C. Ghelardini, “Supraspinal role of protein kinase C in oxaliplatin-induced neuropathy in rat,” Pain, vol. 146, no. 1-2, pp. 141–147, 2009. View at Publisher · View at Google Scholar · View at Scopus
  163. J. Nakamura, K. Kato, Y. Hamada et al., “A protein kinase C-β-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats,” Diabetes, vol. 48, no. 10, pp. 2090–2095, 1999. View at Publisher · View at Google Scholar · View at Scopus
  164. A. I. Vinik, V. Bril, P. Kempler et al., “Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C β-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial,” Clinical Therapeutics, vol. 27, no. 8, pp. 1164–1180, 2005. View at Publisher · View at Google Scholar · View at Scopus
  165. E. Haupt, H. Ledermann, and W. Köpcke, “Benfotiamine in the treatment of diabetic polyneuropathy—a three-week randomized, controlled pilot study (BEDIP study),” International Journal of Clinical Pharmacology and Therapeutics, vol. 43, no. 2, pp. 71–77, 2005. View at Publisher · View at Google Scholar · View at Scopus
  166. A. Stirban, M. Negrean, B. Stratmann et al., “Adiponectin decreases postprandially following a heat-processed meal in individuals with type 2 diabetes: an effect prevented by benfotiamine and cooking method,” Diabetes Care, vol. 30, no. 10, pp. 2514–2516, 2007. View at Publisher · View at Google Scholar · View at Scopus
  167. P. Balakumar, A. Rohilla, P. Krishan, P. Solairaj, and A. Thangathirupathi, “The multifaceted therapeutic potential of benfotiamine,” Pharmacological Research, vol. 61, no. 6, pp. 482–488, 2010. View at Publisher · View at Google Scholar · View at Scopus
  168. N. E. Cameron, T. M. Gibson, M. R. Nangle, and M. A. Cotter, “Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes,” Annals of the New York Academy of Sciences, vol. 1043, pp. 784–792, 2005. View at Publisher · View at Google Scholar · View at Scopus
  169. H. Stracke, A. Lindemann, and K. Federlin, “A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy,” Experimental and Clinical Endocrinology and Diabetes, vol. 104, no. 4, pp. 311–316, 1996. View at Publisher · View at Google Scholar · View at Scopus
  170. H. Yan, Y. Guo, J. Zhang, Z. Ding, W. Ha, and J. J. Harding, “Effect of carnosine, aminoguanidine, and aspirin drops on the prevention of cataracts in diabetic rats,” Molecular Vision, vol. 14, pp. 2282–2291, 2008. View at Google Scholar · View at Scopus
  171. P. Urios, A.-M. Grigorova-Borsos, and M. Sternberg, “Aspirin inhibits the formation of pentosidine, a cross-linking advanced glycation end product, in collagen,” Diabetes Research and Clinical Practice, vol. 77, no. 2, pp. 337–340, 2007. View at Publisher · View at Google Scholar · View at Scopus
  172. K. Green, M. D. Brand, and M. P. Murphy, “Prevention of mitochondrial oxidative damage as a therapeutic strategy in diabetes,” Diabetes, vol. 53, supplement 1, pp. S110–S118, 2004. View at Publisher · View at Google Scholar · View at Scopus
  173. H. Bugger and E. D. Abel, “Mitochondria in the diabetic heart,” Cardiovascular Research, vol. 88, no. 2, pp. 229–240, 2010. View at Publisher · View at Google Scholar · View at Scopus
  174. T. Nishikawa, D. Edelstein, X. L. Du et al., “Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage,” Nature, vol. 404, no. 6779, pp. 787–790, 2000. View at Publisher · View at Google Scholar · View at Scopus
  175. T.-J. Huang, S. A. Price, L. Chilton et al., “Insulin prevents depolarization of the mitochondrial inner membrane in sensory neurons of type 1 diabetic rats in the presence of sustained hyperglycemia,” Diabetes, vol. 52, no. 8, pp. 2129–2136, 2003. View at Publisher · View at Google Scholar · View at Scopus
  176. T.-J. Huang, N. M. Sayers, A. Verkhratsky, and P. Fernyhough, “Neurotrophin-3 prevents mitochondrial dysfunction in sensory neurons of streptozotocin-diabetic rats,” Experimental Neurology, vol. 194, no. 1, pp. 279–283, 2005. View at Publisher · View at Google Scholar · View at Scopus
  177. S. Dikalov, “Cross talk between mitochondria and NADPH oxidases,” Free Radical Biology and Medicine, vol. 51, no. 7, pp. 1289–1301, 2011. View at Publisher · View at Google Scholar · View at Scopus
  178. X. Shen, S. Zheng, N. S. Metreveli, and P. N. Epstein, “Protection of cardiac mitochondria by overexpression of MnSOD reduces diabetic cardiomyopathy,” Diabetes, vol. 55, no. 3, pp. 798–805, 2006. View at Publisher · View at Google Scholar · View at Scopus
  179. S. Matsushima, T. Ide, M. Yamato et al., “Overexpression of mitochondrial peroxiredoxin-3 prevents left ventricular remodeling and failure after myocardial infarction in mice,” Circulation, vol. 113, no. 14, pp. 1779–1786, 2006. View at Publisher · View at Google Scholar · View at Scopus
  180. I. Banmeyer, C. Marchand, A. Clippe, and B. Knoops, “Human mitochondrial peroxiredoxin 5 protects from mitochondrial DNA damages induced by hydrogen peroxide,” FEBS Letters, vol. 579, no. 11, pp. 2327–2333, 2005. View at Publisher · View at Google Scholar · View at Scopus
  181. L. Ernster, P. Forsmark, and K. Nordenbrand, “The mode of action of lipid-soluble antioxidants in biological membranes: relationship between the effects of ubiquinol and vitamin E as inhibitors of lipid peroxidation in submitochondrial particles,” BioFactors, vol. 3, no. 4, pp. 241–248, 1992. View at Google Scholar · View at Scopus
  182. G. T. Chew and G. F. Watts, “Coenzyme Q10 and diabetic endotheliopathy: oxidative stress and the ‘recoupling hypothesis’,” QJM, vol. 97, no. 8, pp. 537–548, 2004. View at Publisher · View at Google Scholar · View at Scopus
  183. M. P. Murphy and R. A. J. Smith, “Drug delivery to mitochondria: the key to mitochondrial medicine,” Advanced Drug Delivery Reviews, vol. 41, no. 2, pp. 235–250, 2000. View at Publisher · View at Google Scholar · View at Scopus
  184. J. S. Armstrong, “Mitochondrial medicine: pharmacological targeting of mitochondria in disease,” British Journal of Pharmacology, vol. 151, no. 8, pp. 1154–1165, 2007. View at Publisher · View at Google Scholar · View at Scopus
  185. K. S. Echtay, M. P. Murphy, R. A. J. Smith, D. A. Talbot, and M. D. Brand, “Superoxide activates mitochondrial uncoupling protein 2 from the matrix side: Studies using targeted antioxidants,” The Journal of Biological Chemistry, vol. 277, no. 49, pp. 47129–47135, 2002. View at Publisher · View at Google Scholar · View at Scopus
  186. R. A. J. Smith, C. M. Porteous, A. M. Gane, and M. P. Murphy, “Delivery of bioactive molecules to mitochondria in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 9, pp. 5407–5412, 2003. View at Publisher · View at Google Scholar · View at Scopus
  187. V. P. Skulachev, “A biochemical approach to the problem of aging: “megaproject” on membrane-penetrating ions. The first results and prospects,” Biochemistry, vol. 72, no. 12, pp. 1385–1396, 2007. View at Publisher · View at Google Scholar · View at Scopus
  188. J. Trnka, F. H. Blaikie, A. Logan, R. A. J. Smith, and M. P. Murphy, “Antioxidant properties of MitoTEMPOL and its hydroxylamine,” Free Radical Research, vol. 43, no. 1, pp. 4–12, 2009. View at Publisher · View at Google Scholar · View at Scopus
  189. M. L. McEwen, P. G. Sullivan, A. G. Rabchevsky, and J. E. Springer, “Targeting mitochondrial function for the treatment of acute spinal cord injury,” Neurotherapeutics, vol. 8, no. 2, pp. 168–179, 2011. View at Publisher · View at Google Scholar · View at Scopus
  190. H. H. Szeto, “Mitochondria-targeted peptide antioxidants: novel neuroprotective agents,” The American Association of Pharmaceutical Scientists Journal, vol. 8, no. 3, pp. E521–E531, 2006. View at Publisher · View at Google Scholar · View at Scopus
  191. M. Cao, J. Jiang, Y. Du, and P. Yan, “Mitochondria-targeted antioxidant attenuates high glucose-induced P38 MAPK pathway activation in human neuroblastoma cells,” Molecular Medicine Reports, vol. 5, no. 4, pp. 929–934, 2012. View at Publisher · View at Google Scholar · View at Scopus
  192. J. A. Harper, K. Dickinson, and M. D. Brand, “Mitochondrial uncoupling as a target for drug development for the treatment of obesity,” Obesity Reviews, vol. 2, no. 4, pp. 255–265, 2001. View at Publisher · View at Google Scholar · View at Scopus
  193. G. R. Drummond, S. Selemidis, K. K. Griendling, and C. G. Sobey, “Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets,” Nature Reviews Drug Discovery, vol. 10, no. 6, pp. 453–471, 2011. View at Publisher · View at Google Scholar · View at Scopus
  194. T. J. Guzik, S. Mussa, D. Gastaldi et al., “Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase,” Circulation, vol. 105, no. 14, pp. 1656–1662, 2002. View at Publisher · View at Google Scholar · View at Scopus
  195. V. Thallas-Bonke, S. R. Thorpe, M. T. Coughlan et al., “Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-α-dependent pathway,” Diabetes, vol. 57, no. 2, pp. 460–469, 2008. View at Publisher · View at Google Scholar · View at Scopus